Spruce Biosciences (SPRB) Competitors $0.55 +0.02 (+3.79%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SPRB vs. IGNY, ORMP, ACAB, ONCY, IFRX, BYSI, PWUP, OPTN, IOBT, and CHRSShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Ignyte Acquisition (IGNY), Oramed Pharmaceuticals (ORMP), Atlantic Coastal Acquisition Corp. II (ACAB), Oncolytics Biotech (ONCY), InflaRx (IFRX), BeyondSpring (BYSI), PowerUp Acquisition (PWUP), OptiNose (OPTN), IO Biotech (IOBT), and Coherus BioSciences (CHRS). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Ignyte Acquisition Oramed Pharmaceuticals Atlantic Coastal Acquisition Corp. II Oncolytics Biotech InflaRx BeyondSpring PowerUp Acquisition OptiNose IO Biotech Coherus BioSciences Ignyte Acquisition (NASDAQ:IGNY) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Do insiders and institutionals have more ownership in IGNY or SPRB? 61.1% of Ignyte Acquisition shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 19.9% of Ignyte Acquisition shares are held by insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer IGNY or SPRB? Spruce Biosciences received 39 more outperform votes than Ignyte Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformIgnyte AcquisitionN/AN/ASpruce BiosciencesOutperform Votes3960.94% Underperform Votes2539.06% Do analysts prefer IGNY or SPRB? Spruce Biosciences has a consensus price target of $5.00, suggesting a potential upside of 812.08%. Given Spruce Biosciences' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Ignyte Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ignyte Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ASpruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility and risk, IGNY or SPRB? Ignyte Acquisition has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Which has better earnings and valuation, IGNY or SPRB? Ignyte Acquisition has higher earnings, but lower revenue than Spruce Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIgnyte AcquisitionN/AN/A-$490KN/AN/ASpruce Biosciences$10.09M2.24-$47.92M-$1.03-0.53 Is IGNY or SPRB more profitable? Ignyte Acquisition has a net margin of 0.00% compared to Spruce Biosciences' net margin of -450.38%. Ignyte Acquisition's return on equity of 365.46% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ignyte AcquisitionN/A 365.46% -0.83% Spruce Biosciences -450.38%-59.94%-45.38% Does the media favor IGNY or SPRB? In the previous week, Spruce Biosciences had 2 more articles in the media than Ignyte Acquisition. MarketBeat recorded 2 mentions for Spruce Biosciences and 0 mentions for Ignyte Acquisition. Ignyte Acquisition's average media sentiment score of 0.00 beat Spruce Biosciences' score of -0.32 indicating that Ignyte Acquisition is being referred to more favorably in the media. Company Overall Sentiment Ignyte Acquisition Neutral Spruce Biosciences Neutral SummarySpruce Biosciences beats Ignyte Acquisition on 7 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.64M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.539.93115.5615.18Price / Sales2.24381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book0.295.324.665.02Net Income-$47.92M$153.56M$119.06M$225.46M7 Day Performance-3.42%0.11%0.80%0.37%1 Month Performance21.82%15.22%5.65%3.57%1 Year Performance-51.05%41.14%36.76%29.44% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences3.0243 of 5 stars$0.55+3.8%$5.00+812.1%-51.1%$22.64M$10.09M-0.5320IGNYIgnyte AcquisitionN/A$13.05+14.5%N/AN/A$95.00MN/A0.003Gap DownHigh Trading VolumeORMPOramed Pharmaceuticals1.7473 of 5 stars$2.31-2.5%N/A+35.7%$94.18M$1.34M4.5310News CoverageACABAtlantic Coastal Acquisition Corp. IIN/A$11.45+2.6%N/A+9.0%$93.51MN/A0.004High Trading VolumeONCYOncolytics Biotech2.0702 of 5 stars$1.22-0.4%$4.00+229.2%-27.2%$92.72MN/A-4.3430Positive NewsIFRXInflaRx3.4101 of 5 stars$1.55-1.3%$13.50+771.0%-2.5%$91.26M$70,000.00-1.7460Upcoming EarningsShort Interest ↓News CoverageBYSIBeyondSpringN/A$2.33+3.1%N/A+120.4%$90.94M$1.88M0.0080Positive NewsPWUPPowerUp AcquisitionN/A$11.69+1.1%N/A-3.3%$90.83MN/A0.00N/ANews CoveragePositive NewsOPTNOptiNose3.411 of 5 stars$0.78+1.5%$4.00+411.1%-45.7%$88.46M$75.06M-2.17190Gap DownIOBTIO Biotech3.3411 of 5 stars$1.32+9.1%$9.33+607.1%+36.8%$86.96MN/A-0.9230Short Interest ↓Positive NewsGap UpCHRSCoherus BioSciences3.8143 of 5 stars$0.75-4.0%$7.13+846.7%-77.4%$86.34M$308.13M-1.88246Upcoming Earnings Related Companies and Tools Related Companies Ignyte Acquisition Competitors Oramed Pharmaceuticals Competitors Atlantic Coastal Acquisition Corp. II Competitors Oncolytics Biotech Competitors InflaRx Competitors BeyondSpring Competitors PowerUp Acquisition Competitors OptiNose Competitors IO Biotech Competitors Coherus BioSciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPRB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRB Stock Alerts